162 results on '"Taro Takami"'
Search Results
2. Distinction of Drug-Induced Liver Injury From Autoimmune Hepatitis in Patients With Acute Liver Injury: Proposal of a Combination of Diagnostic Scores
- Author
-
Keisuke Kakisaka, Nobuaki Nakayama, Kotaro Kumagai, Takuro Hisanaga, Takayuki Kondo, Toru Setsu, Shunsuke Sato, Yohei Kooka, Kei Endo, Yuichi Yoshida, Takayoshi Oikawa, Hidekatsu Kuroda, Akio Miyasaka, Ryuzo Abe, Taka-aki Nakada, Yoshihiro Ikura, Kenichi Harada, Takuya Genda, Shuji Terai, Naoya Kato, Taro Takami, Akio Ido, Satoshi Mochida, Takayuki Matsumoto, and Atsushi Tanaka
- Published
- 2023
3. A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension
- Author
-
Tsuyoshi Ishikawa, Maho Egusa, Tsuyoshi Fujioka, Natsuko Nishiyama, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Norikazu Tanabe, Takashi Oono, Issei Saeki, and Taro Takami
- Subjects
Gastroenterology - Abstract
We previously reported liver stiffness (LS) as a prognostic predictor of portosystemic shunt (PSS) occlusion. This study aims to reinvestigate the predictive factors of the model for end-stage liver disease-sodium (MELD-Na) score amelioration following balloon-occluded retrograde transvenous obliteration (BRTO) and to evaluate the postoperative prognoses of patients with portal hypertension by using newly identified factors.Seventy-five patients who underwent BRTO between 2008 and 2021 were retrospectively enrolled. The MELD-Na scores were calculated preoperatively and one month postoperatively. We monitored long-term outcomes and analyzed postoperative survival.At one month postoperatively, the MELD-Na score decreased in 46 (61.3%) patients. Univariate analyses revealed a significant association of the score amelioration with nine factors, including lower LS levels and a higher international normalized ratio (INR). A multivariate logistic regression analysis with receiver operating characteristic curve analyses identified preoperative LS levels and INR as significant independent predictors of the postoperative MELD-Na score amelioration, with optimal cutoffs of 28.1 kPa and 1.06, respectively. The combination of LS 28.1 kPa and INR ≥ 1.06 showed a sensitivity and specificity of 84.8% and 75.9% for the prediction of the score amelioration, respectively. For the propensity score model, we matched 24 patients with similar age, sex, MELD-Na score, and concomitant hepatocellular carcinoma. Kaplan-Meier analysis determined significantly higher cumulative survival rates in patients with LS 28.1 kPa and INR ≥ 1.06 than in other populations.A combination of LS and INR can predict the MELD-Na score amelioration and prognosis improvement following PSS occlusion.
- Published
- 2022
4. Drastic Improvement in Hepatitis B/C Virus-induced Decompensated Liver Cirrhosis Treated by Total Management Consisting of Interventional Radiology, Endoscopy, and Pharmacotherapy
- Author
-
Tatsuro, Nishimura, Tsuyoshi, Ishikawa, Daiki, Kawamoto, Ryo, Sasaki, Takashi, Matsuda, and Taro, Takami
- Subjects
Liver Cirrhosis ,Internal Medicine ,Humans ,Hepacivirus ,General Medicine ,Radiology, Interventional ,Hepatitis B ,Hepatitis C ,Antiviral Agents ,Endoscopy, Gastrointestinal - Abstract
Recent advances in antiviral therapy have enabled control of the hepatitis virus; however, these do not completely eliminate the pathological condition of liver disease, and portal hypertension remains a clinical problem. We herein report a case of hepatitis B virus/hepatitis C virus (HBV/HCV)-induced decompensated liver cirrhosis for which total management consisting of interventional radiology and endoscopy, based on the evidence of our clinical studies, followed by antiviral therapy for co-infection with HBV and HCV was successful. This case clearly indicates the effective timing of total management, suggesting that it prolongs the vital prognosis in addition to improving the hepatic function.
- Published
- 2022
5. Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma
- Author
-
Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono, Maiko Nishi, Isao Hidaka, Shinya Kuwashiro, Shogo Shiratsuki, Keiji Matsuura, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Takashi Oono, Takuro Hisanaga, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takahiro Yamasaki, and Taro Takami
- Subjects
Cancer Research ,Oncology ,hepatocellular carcinoma ,atezolizumab ,bevacizumab ,alpha-fetoprotein ,des-gamma-carboxy prothrombin ,immune checkpoint inhibitor - Abstract
Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predictors of treatment efficacy of atezo/bev for unresectable HCC. Factors associated with treatment response were examined, focusing on tumor markers. In the high-alpha-fetoprotein (AFP) group (baseline AFP ≥ 20 ng/mL), a decrease in AFP level > 30% was an independent predictor of objective response (odds ratio, 5.517; p = 0.0032). In the low-AFP group (baseline AFP < 20 ng/mL), baseline des-gamma-carboxy prothrombin (DCP) level < 40 mAU/mL was an independent predictor of objective response (odds ratio, 3.978; p = 0.0206). The independent predictors of early progressive disease were an increase in AFP level ≥ 30% at 3 weeks (odds ratio, 4.077; p = 0.0264) and the presence of extrahepatic spread (odds ratio, 3.682; p = 0.0337) in the high-AFP group and up-to-seven criteria, OUT (odds ratio, 15.756; p = 0.0257) in the low-AFP group. In atezo/bev therapy, focusing on early AFP changes, baseline DCP, and tumor burden of up-to-seven criteria are useful in predicting response to treatment.
- Published
- 2023
- Full Text
- View/download PDF
6. Induction hepatic arterial infusion chemotherapy with concurrent radiotherapy followed by surgery for hepatocellular carcinoma with massive portal vein tumor thrombosis
- Author
-
Yuta Kimura, Yukio Tokumitsu, Yoshitaro Shindo, Hiroto Matsui, Satoshi Matsukuma, Issei Saeki, Taro Takami, Takahiro Yamasaki, Tatsuya Ioka, and Hiroaki Nagano
- Abstract
Background The prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is very poor, and the optimal treatment remains controversial. The aim of this study was to examine the safety and feasibility of our multimodal treatment. Methods This was a single-institution, retrospective case series. From 2013 to 2018, induction hepatic arterial infusion chemotherapy (HAIC) with concurrent radiotherapy (RT) was given to 20 consecutive patients with HCC harboring PVTT in the main portal trunk or first branch, even with intrahepatic and extrahepatic metastasis. When the cancers including thrombus and metastatic disease were well-controlled, surgical resection was considered. When macroscopic complete resection was achieved, two courses of HAIC were added as adjuvant therapy, whereas patients who had remnant disease after surgery were provided treatment according to the type of lesion. Results No treatment-related deaths were noted. The objective response rate and disease control rate were 35.0% and 65.0%, respectively. After induction treatment, 10 of 20 patients underwent surgery. Postoperative complications (Clavien-Dindo Grade III or more) were observed in three cases, and median postoperative hospital stay was 15.5 days. Median survival time of all 20 patients was 14.5 months, and that in patients who underwent surgery was significantly longer than that in patients with unresectable HCC (19.5 months vs 9.0 months, p = 0.0018). Conclusions Induction treatment followed by surgery was safe and feasible for HCC with massive PVTT. Surgical resection might be oncologically appropriate for selected patients after induction treatment even with advanced stage HCC.
- Published
- 2023
7. Crystal-Storing Histiocytosis of the Stomach
- Author
-
Atsushi Goto, Koichi Hamabe, Keisuke Seto, Shinichi Hashimoto, Jun Nishikawa, and Taro Takami
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
8. Comparison of two primer-probe sets of Fusobacterium nucleatum using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples
- Author
-
Yuko Yamaoka, Mai Sasai, Yutaka Suehiro, Shinichi Hashimoto, Atsushi Goto, Naoki Yamamoto, Nobuaki Suzuki, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Toshihiko Matsumoto, Tomomi Hoshida, Michiko Koga, Takeya Tsutsumi, Lay A Lim, Yasuo Matsubara, Shinobu Tomochika, Shin Yoshida, Shoichi Hazama, Hiroshi Yotsuyanagi, Hiroaki Nagano, Isao Sakaida, Taro Takami, and Takahiro Yamasaki
- Subjects
Adenoma ,Feces ,Fusobacterium nucleatum ,Clinical Biochemistry ,Humans ,General Medicine ,Colorectal Neoplasms ,Real-Time Polymerase Chain Reaction - Abstract
Background: Although faecal DNA testing of Fusobacterium nucleatum ( Fn) is expected to be useful for colorectal neoplasia detection, there is no standardized quantification method of Fn. We performed this study to establish a possible standardized method. Methods: In this study, 322 participants including 71 subjects without colorectal neoplasia (control group), 31 patients with non-advanced colorectal adenoma, 93 patients with advanced colorectal adenoma, and 127 patients with colorectal cancer were enrolled. Faecal Fn were quantified by droplet digital PCR (ddPCR) using two PCR primer-probe sets reported previously that are tentatively named Fn1 and Fn2. Fn1 has been used in ddPCR by us and Fn2 has been widely used in quantitative real-time PCR. Results: The Fn copy number using Fn1 was five times higher than that using Fn2, with a linear relationship shown between them. Receiver operating characteristic curve analysis showed the area under the curve (AUC) to be almost the same between Fn1 and Fn2 in discriminating between the control group and the colorectal cancer group (AUC = 0.81 and 0.81, respectively), and between the control/non-advanced colorectal adenoma group and the advanced colorectal adenoma/colorectal cancer group (AUC = 0.74 and 0.74, respectively). Conclusions: As the diagnostic performance was quite similar between Fn1 and Fn2, ddPCR-based Fn testing using Fn1 and Fn2 could be a possible standardized method for a colorectal neoplasia screening test, considering that Fn levels quantified by Fn1 are about five times higher than those by Fn2.
- Published
- 2022
9. Comparison of Duodenal Stenting and Gastrojejunostomy for Duodenal Obstruction with Biliary Obstruction
- Author
-
Hirofumi Harima, Seiji Kaino, Yuko Fujimoto, Shogo Amano, Michitaka Kawano, Shigeyuki Suenaga, Toshiyuki Uekitani, Manabu Sen-Yo, Miyuki Kaino, Taro Takami, and Isao Sakaida
- Subjects
Cholestasis ,Palliative Care ,Gastric Bypass ,Gastroenterology ,Humans ,Stents ,Surgery ,Duodenal Obstruction ,Retrospective Studies - Abstract
The best palliation for double obstruction (duodenal obstruction with biliary obstruction) remains unclear. We aimed to compare outcomes of duodenal stenting (DuS) with gastrojejunostomy (GJ) and identify factors associated with survival time and time to recurrent biliary obstruction (TRBO).Patients who underwent DuS or GJ combined with biliary stenting for double obstruction due to unresectable malignancy were retrospectively enrolled.In total, 111 patients were included; 84 underwent DuS, and 27 underwent GJ. The weighted survival time of the DuS group was significantly shorter than that of the GJ group (86 days vs 134 days, P 0.01). Although the weighted TRBO was not significantly different between the two groups, when limited to patients with distal duodenal obstruction, the weighted TRBO was significantly longer in the DuS group than in the GJ group (207 days vs. 32 days, P 0.01). GJ for distal duodenal obstruction was identified as the factor with the highest hazard ratio and was associated with a shorter TRBO (hazard ratio 8.5, P 0.01).Regarding survival time, GJ should be considered the primary treatment for patients with double obstruction. However, for patients with distal duodenal obstruction, DuS should be considered because GJ may be a risk factor for a shorter TRBO.
- Published
- 2022
10. Diagnostic Criteria for Acute-on-Chronic Liver Failure and Related Disease Conditions in Japan
- Author
-
Satoshi Mochida, Nobuaki Nakayama, Shuji Terai, Hitoshi Yoshiji, Masahito Shimizu, Akio Ido, Kazuaki Inoue, Takuya Genda, Yasuhiro Takikawa, Taro Takami, Naoya Kato, Masanori Abe, Ryuzo Abe, Ayano Inui, Hiromasa Ohira, Mureo Kasahara, Kazuaki Chayama, Kiyoshi Hasegawa, and Atsushi Tanaka
- Subjects
Infectious Diseases ,Hepatology - Abstract
The Intractable Hepato-Biliary Disease Study Group of Japan, sponsored by the Ministry of Health, Labor and Wealth, proposed in 2018 that patients with cirrhosis and a Child-Pugh score of 5-9 should be diagnosed as having acute-on-chronic liver failure (ACLF) when a deterioration of liver function ("serum bilirubin level of 5.0 mg/dl or more" and "prothrombin time value of 40% or less of the standardized values and/or international normalization rates of 1.5 or more") caused by severe liver damage develops within 28 days after an acute insult, including alcohol abuse, bacterial infection, gastrointestinal bleeding, and the exacerbation of underlying liver diseases. Disease severity can be classified into 4 grades depending on the extent of the deterioration in organ functions, including liver, kidney, cerebral, blood coagulation, circulatory and respiratory functions. The Study Group has since performed an annual nationwide survey of patients with ACLF diagnosed according to the proposed diagnostic criteria as well as those with disease conditions related to ACLF. A total of 501 patients, including 183 patients diagnosed as having ACLF, seen between 2017 and 2019 were enrolled, and univariate and multivariate analyses revealed that the proposed diagnostic criteria were useful for identifying cirrhotic patients with an unfavorable outcome following an acute insult. Consequently, the Study Group determined that the proposed diagnostic criteria should be used in both clinical practice and clinical research as formal diagnostic criteria.
- Published
- 2022
11. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma
- Author
-
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, Tomomi Hoshida, Norikazu Tanabe, Takashi Oono, Daiki Kawamoto, Tatsuro Nishimura, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Mototsugu Shimokawa, Akihiro Tamori, Norifumi Kawada, Yasuyuki Tamai, Motoh Iwasa, Hayato Nakagawa, Hiroaki Nagano, Taro Takami, and Takahiro Yamasaki
- Subjects
Hepatology - Published
- 2023
12. Supplementary Table 1 from Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine–Induced Hepatocarcinogenesis
- Author
-
Snorri S. Thorgeirsson, Valentina M. Factor, Elizabeth A. Conner, Luis E. Gomez-Quiroz, Koichi Uchida, Pal Kaposi-Novak, and Taro Takami
- Abstract
Supplementary Table 1 from Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine–Induced Hepatocarcinogenesis
- Published
- 2023
13. Supplementary Methods and Materials from Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine–Induced Hepatocarcinogenesis
- Author
-
Snorri S. Thorgeirsson, Valentina M. Factor, Elizabeth A. Conner, Luis E. Gomez-Quiroz, Koichi Uchida, Pal Kaposi-Novak, and Taro Takami
- Abstract
Supplementary Methods and Materials from Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine–Induced Hepatocarcinogenesis
- Published
- 2023
14. Data from Loss of Hepatocyte Growth Factor/c-Met Signaling Pathway Accelerates Early Stages of N-nitrosodiethylamine–Induced Hepatocarcinogenesis
- Author
-
Snorri S. Thorgeirsson, Valentina M. Factor, Elizabeth A. Conner, Luis E. Gomez-Quiroz, Koichi Uchida, Pal Kaposi-Novak, and Taro Takami
- Abstract
Hepatocyte growth factor (HGF) has been reported to have both positive and negative effects on carcinogenesis. Here, we show that the loss of c-Met signaling in hepatocytes enhanced rather than suppressed the early stages of chemical hepatocarcinogenesis. c-Met conditional knockout mice (c-metfl/fl, AlbCre+/−; MetLivKO) treated with N-nitrosodiethylamine developed significantly more and bigger tumors and with a shorter latency compared with control (w/w, AlbCre+/−; Cre-Ctrl) mice. Accelerated tumor development was associated with increased rate of cell proliferation and prolonged activation of epidermal growth factor receptor (EGFR) signaling. MetLivKO livers treated with N-nitrosodiethylamine also displayed elevated lipid peroxidation, decreased ratio of reduced glutathione to oxidized glutathione, and up-regulation of superoxide dismutase 1 and heat shock protein 70, all consistent with increased oxidative stress. Likewise, gene expression profiling done at 3 and 5 months after N-nitrosodiethylamine treatment revealed up-regulation of genes associated with cell proliferation and stress responses in c-Met mutant livers. The negative effects of c-Met deficiency were reversed by chronic p.o. administration of antioxidant N–acetyl–l-cysteine. N–acetyl–l-cysteine blocked the EGFR activation and reduced the N-nitrosodiethylamine–initiated hepatocarcinogenesis to the levels of Cre-Ctrl mice. These results argue that intact HGF/c-Met signaling is essential for maintaining normal redox homeostasis in the liver and has tumor suppressor effect(s) during the early stages of N-nitrosodiethylamine–induced hepatocarcinogenesis. [Cancer Res 2007;67(20):9844–51]
- Published
- 2023
15. A case of multiple glucagonomas with no clinical manifestations of excess glucagon despite hyperglucagonemia
- Author
-
Shogo Amano, Shigeyuki Suenaga, Kaori Hamamoto, Shoko Yada, Takanori Tsuyama, Shuhei Shinoda, Yuya Tanaka, Yoshihiro Takemoto, Eijiro Harada, Katsuya Tanabe, Shunichiro Asahara, Kazunobu Hoshii, and Taro Takami
- Subjects
General Medicine - Published
- 2023
16. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab
- Author
-
Yurika Yamauchi, Issei Saeki, Takahiro Yamasaki, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Tatsuro Nishimura, Norikazu Tanabe, Takashi Oono, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Yoshio Marumoto, Satoshi Matsukuma, Yoshitaro Shindo, Yukio Tokumitsu, Sota Yoshimine, Junichi Murakami, Toshiki Tanaka, Sotai Kimura, Yoshinobu Hoshii, Kimikazu Hamano, Hiroaki Nagano, and Taro Takami
- Subjects
Infectious Diseases ,Hepatology - Published
- 2023
17. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis
- Author
-
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Norifumi Kawada, Masayuki Kurosaki, Akio Ido, Daiki Miki, Hitoshi Yoshiji, Yasuhiro Takikawa, Ryotaro Sakamori, Yoichi Hiasa, Kazuhiko Nakao, Naoya Kato, Yoshiyuki Ueno, Hiroshi Yatsuhashi, Yoshito Itoh, Ryosuke Tateishi, Goki Suda, Taro Takami, Yasunari Nakamoto, Yasuhiro Asahina, Kentaro Matsuura, Taro Yamashita, Tatsuya Kanto, Norio Akuta, Shuji Terai, Masahito Shimizu, Satoshi Sobue, Tomokatsu Miyaki, Akihiro Moriuchi, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, and Tetsuo Takehara
- Subjects
Liver Cirrhosis ,Male ,Carcinoma, Hepatocellular ,Sustained Virologic Response ,Liver Neoplasms ,Gastroenterology ,Humans ,Hepacivirus ,Hepatitis C, Chronic ,Antiviral Agents - Abstract
Direct-acting antiviral (DAA) therapy enables a high rate of sustained virologic response (SVR) in patients with hepatitis C virus associated cirrhosis. However, the impact of DAA therapy on liver-related events in patients with cirrhosis is unclear.A total of 350 patients with compensated and decompensated cirrhosis administered DAA therapy at 29 Japanese hospitals were enrolled (Child-Pugh class A [CP-A]: 195 patients, CP-B: 131 patients and CP-C: 24 patients).The SVR rates of patients with CP-A, CP-B and CP-C were 96.9%, 93.1% and 83.3%, respectively (p = 0.006). Seventy patients developed hepatocellular carcinoma (HCC), and male sex, previous HCC treatment, platelet counts 10.0 × 10HCC development and mortality in patients with CP-B were not different from those with CP-A. On the other hand, in patients with CP-C, the development of HCC and decompensated cirrhotic events requiring hospital admission, and death were frequent.University Hospital Medical Information Network (UMIN000036150).
- Published
- 2022
18. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer
- Author
-
Yutaka Suehiro, Shigeyuki Suenaga, Yuki Kunimune, Shoko Yada, Kaori Hamamoto, Takanori Tsuyama, Shogo Amano, Hiroto Matsui, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Tomomi Hoshida, Toshihiko Matsumoto, Yuko Fujimoto, Seiji Kaino, Keiko Shinjo, Yutaka Kondo, Isao Sakaida, Taro Takami, Hiroaki Nagano, and Takahiro Yamasaki
- Subjects
Cancer Research ,Oncology ,General Medicine - Abstract
Introduction: We previously developed a novel methylation assay, the combined restriction digital PCR (CORD) assay, consisting of treatment of DNA with methylation-sensitive restriction enzymes and droplet digital PCR. Methods: In this study, we assessed the diagnostic performance of serum methylated Homeobox A1 (mHOXA1) and methylated somatostatin (mSST) using the CORD assay in combination with CA19-9 for pancreatic cancer using serum samples from 82 healthy individuals, 13 patients with benign pancreatic disease, 3 patients with branched-duct intraductal papillary mucinous neoplasm, and 91 patients with pancreatic cancer. Results: For the single marker tests, sensitivity for all stages of pancreatic cancer, stage I cancer, and specificity were, respectively, 71.4%, 50.0%, and 94.9% for CA19-9; 51.6%, 68.8%, and 90.8% for mHOXA1; and 50.1%, 68.8%, and 94.9% for mSST. Those for the combined marker tests were, respectively, 86.8%, 81.3%, and 85.7% for combined mHOXA1 and CA19-9; 86.8%, 87.5%, and 89.8% for combined mSST and CA19-9; and 89.0%, 87.5%, and 85.7% for all three markers combined. Conclusion: The combination of mHOXA1 and mSST with CA19-9 appears to be useful to detect pancreatic cancer even at an early stage.
- Published
- 2022
19. Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension
- Author
-
Maho Egusa, Tatsuro Nishimura, Tsuyoshi Ishikawa, Taro Takami, Issei Saeki, Ryo Sasaki, Daiki Kawamoto, and Isao Sakaida
- Subjects
medicine.medical_specialty ,education.field_of_study ,Portopulmonary hypertension ,Univariate analysis ,Hepatology ,medicine.diagnostic_test ,business.industry ,Population ,Interventional radiology ,medicine.disease ,Inferior vena cava ,Infectious Diseases ,medicine.vein ,medicine.artery ,Ascending aorta ,medicine ,Portal hypertension ,Radiology ,education ,business ,Blood urea nitrogen - Abstract
AIM This study aimed to demonstrate the feasibility of identifying candidates of portopulmonary hypertension (PoPH) from general portal hypertension patients based on chest computed tomography (CT) results. METHODS One hundred and thirty patients with portal hypertension who had undergone interventional radiology therapies at our hospital between August 2011 and July 2021 were included, and preoperative clinical data were collected. Suspicious PoPH was defined as main pulmonary artery diameter (mPA-D) ≥ 29 mm or the ratio of mPA-D to ascending aorta diameter (mPA-D/aAo-D) ≥ 1.0, and probable PoPH as mPA-D ≥ 33 mm based on the chest CT. Prevalence of suspicious and probable PoPH was evaluated, and the differences in clinical characteristics of each population were compared. RESULTS Overall, 29 (22.3%) and 5 (3.8%) patients were categorized as suspicious and probable PoPH, respectively. Univariate analyses revealed that female sex, higher shortest diameter of inferior vena cava, presence of portosystemic shunts ≥ 5 mm, and lower blood urea nitrogen levels were significantly associated with suspicious PoPH (P < 0.05). Multivariate analysis identified all four factors as significantly independent determinants of suspicious PoPH (P < 0.05). In addition, among the population of suspicious PoPH, there were significant differences in seven parameters, including total bilirubin levels and spleen volume between patients with and without probable PoPH (P < 0.05). However, no significant independent indicators of probable PoPH were found. CONCLUSIONS CT-based measurements of mPA-D and mPA-D/aAo-D have the potential to screen patients with suspicious PoPH in clinical practice focused on portal hypertension. This article is protected by copyright. All rights reserved.
- Published
- 2021
20. Liquid Biopsy Test Based on a Sensitive DNA Methylation Assay for Diagnosing Hepatocellular Carcinoma:Which Is a Better Marker, Methylated SST Or SEPT9?
- Author
-
Ayano YAMASAKI, Yutaka SUEHIRO, Tomomi HOSHIDA, Issei SAEKI, Yurika YAMAUCHI(KOTOH), Toshihiko MATSUMOTO, Taro TAKAMI, Isao SAKAIDA, and Takahiro YAMASAKI
- Subjects
General Medicine - Published
- 2021
21. Promotion of intrahospital referral of hepatitis virus-positive patients to hepatology specialists through interprofessional collaboration, including clinical laboratory technicians
- Author
-
Takashi Oono, Reo Kawano, Isao Hidaka, Tsuyoshi Ishikawa, Takahiro Yamasaki, Miyuki Masui, Toshihiko Matsumoto, Aki Fujinaga, Takuro Hisanaga, Taro Takami, Isao Sakaida, Issei Saeki, and Yoshio Marumoto
- Subjects
Hepatitis virus ,medicine.medical_specialty ,Hepatology ,Referral ,business.industry ,media_common.quotation_subject ,Promotion (rank) ,Family medicine ,Internal medicine ,medicine ,business ,Laboratory technicians ,media_common - Published
- 2021
22. The Evaluation of Transmural Healing by Low-dose Computed Tomography Enterography in Patients with Crohn's Disease
- Author
-
Hiroyuki Fujimura, Shinichi Hashimoto, Kensaku Shimizu, Hideko Onoda, Masahiro Tanabe, Mayumi Higashi, Ryo Ogawa, Atsushi Goto, Koichi Hamabe, Jun Nishikawa, Katsuyoshi Ito, and Taro Takami
- Subjects
C-Reactive Protein ,Crohn Disease ,Internal Medicine ,Humans ,General Medicine ,Tomography, X-Ray Computed ,Serum Albumin ,Retrospective Studies - Abstract
Objective Transmural healing (TH) has been attracting attention as a new therapeutic target for Crohn's disease, but there are few clinical data on TH in Japan. We introduced low-dose computed tomography enterography (CTE) as a monitoring method for Crohn's disease and retrospectively investigated the accuracy of evaluating TH by CTE. Methods Among Crohn's disease patients who underwent low-dose CTE at our hospital from January 2009 to March 2021, 122 patients who underwent colonoscopy or balloon endoscopy within 2 weeks were included. Results of radiological and endoscopic examinations were reviewed independently by radiologists and gastrointestinal endoscopists, respectively. The concordance rate of the diagnosis between CTE and endoscopy was evaluated. Results Twenty-six patients (21.3%) achieved TH, and the kappa index was 0.743. On comparing the TH and non-TH groups, the Crohn's disease activity index (p=0.02), endoscopic healing rate (p0.001), serum albumin (p=0.043), and serum C-reactive protein level (p=0.018) showed significant differences. Among the 122 patients, 69 (56.5%) showed concordance between the diagnosis of CTE and endoscopy, and 22 (18.0%) achieved both TH and endoscopic healing. Conclusion This study provides real-world data on Crohn's disease evaluated with low-dose CTE in Japan. The TH criterion used in this study has a high kappa coefficient and can be used reproducibly in many institutions.
- Published
- 2022
23. Successful Management With Dual Therapy of Lenvatinib and Macitentan for HCC With Portopulmonary Hypertension
- Author
-
Ryo Sasaki, Yasuaki Wada, Issei Saeki, Isao Sakaida, Takashi Matsuda, Masafumi Yano, Taro Takami, and Tsuyoshi Ishikawa
- Subjects
Endothelin Receptor Antagonists ,Liver Cirrhosis ,Male ,Oncology ,Cardiac Catheterization ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Medication Therapy Management ,medicine.drug_class ,Tyrosine-kinase inhibitor ,chemistry.chemical_compound ,Hepatitis B, Chronic ,Internal medicine ,Hypertension, Portal ,medicine ,Humans ,Protein Kinase Inhibitors ,Aged ,Macitentan ,Pulmonary Arterial Hypertension ,Sulfonamides ,Portopulmonary hypertension ,Hepatology ,business.industry ,Endothelin receptor antagonist ,Phenylurea Compounds ,Liver Neoplasms ,Protein-Tyrosine Kinases ,medicine.disease ,respiratory tract diseases ,Dasatinib ,Pyrimidines ,Treatment Outcome ,chemistry ,Quinolines ,Portal hypertension ,Tomography, X-Ray Computed ,business ,Lenvatinib ,Chronic myelogenous leukemia ,medicine.drug - Abstract
Portopulmonary hypertension (PoPH) is a subcategory of pulmonary arterial hypertension (PAH) associated with portal hypertension (PH). Certain drugs, including dasatinib, a tyrosine kinase inhibitor (TKI) for chronic myelogenous leukemia, have been identified as risk factors for the development of PAH.(1) However, although TKIs, such as lenvatinib, have been widely used for the treatment of HCC, no reports have demonstrated the association of TKIs for HCC with PAH.
- Published
- 2021
24. An autopsy case of primary malignant lymphoma of the spleen with acute liver failure and respiratory failure
- Author
-
Ryo Sasaki, Hiroshi Itoh, Yurika Kotoh, Isao Hidaka, Taro Takami, Issei Saeki, Tsuyoshi Ishikawa, Isao Sakaida, Takashi Matsuda, and Takashi Oono
- Subjects
Malignant lymphoma ,Pathology ,medicine.medical_specialty ,medicine.anatomical_structure ,Hepatology ,Respiratory failure ,business.industry ,medicine ,Liver failure ,Spleen ,Autopsy case ,business - Published
- 2021
25. Short-term Effects of Hepatic Arterial Buffer Responses Induced by Partial Splenic Embolization on the Hepatic Function of Patients with Cirrhosis According to the Child-Pugh Classification
- Author
-
Issei Saeki, Takuya Iwamoto, Taro Takami, Tatsuro Nishimura, Ryo Sasaki, Takashi Matsuda, Tsuyoshi Ishikawa, Isao Hidaka, and Isao Sakaida
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Cirrhosis ,Child-Pugh score ,hepatic function ,030204 cardiovascular system & hematology ,Gastroenterology ,Hypersplenism ,Group B ,Hepatic function ,03 medical and health sciences ,Hepatic Artery ,0302 clinical medicine ,Partial splenic embolization ,Internal medicine ,medicine.artery ,polycyclic compounds ,Internal Medicine ,medicine ,Humans ,hepatic arterial buffer response ,Arterial hemodynamics ,Common hepatic artery ,business.industry ,partial splenic embolization ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Embolization, Therapeutic ,digestive system diseases ,CHILD-PUGH CLASSIFICATION ,Splenic infarction ,Original Article ,030211 gastroenterology & hepatology ,business - Abstract
Objective This study primarily aimed to investigate the short-term effects of partial splenic embolization (PSE) on the Child-Pugh score and identify predictive factors for changes in the score caused by PSE. The secondary aim was to analyze changes in various parameters at one month postoperatively using these identified factors. Methods Between September 2007 and December 2019, 118 patients with cirrhosis and hypersplenism underwent PSE at our hospital. Testing was conducted preoperatively and at one month after PSE. Results Overall, the Child-Pugh score was not significantly changed postoperatively. The Child-Pugh score before PSE was identified as the strongest independent predictor of ameliorated and deteriorated Child-Pugh scores after PSE. Higher pretreatment Child-Pugh scores were correlated with higher posttreatment amelioration rates of the score. A significant decrease in the portal vein diameter and a significant increase in the common hepatic artery diameter were evident at the same level postoperatively in 64 patients with Child-Pugh class A (group A) and in 54 patients with Child-Pugh class B or C (group B/C) preoperatively. According to Murray's Law, PSE resulted in decreased portal venous flow and increased hepatic arterial flow, suggesting a hepatic arterial buffer response (HABR) induced by the procedure. Despite equivalent splenic infarction rates and similar posttreatment changes in hepatic hemodynamics, PSE significantly increased the Child-Pugh score of group A; however, the procedure significantly decreased the score of group B/C. Conclusion Considering original portal venous-hepatic arterial hemodynamics, PSE is expected to produce HABR-mediated hepatic functional improvements in cirrhosis patients with Child-Pugh class B/C.
- Published
- 2021
26. EUS-guided biliary drainage in a patient after postcholecystectomy complete biliary transection (with video)
- Author
-
Hirofumi Harima, Harumi Suehiro, Michitaka Kawano, Tadasuke Hanazono, Kenji Mori, and Taro Takami
- Subjects
Hepatology ,Gastroenterology ,Radiology, Nuclear Medicine and imaging - Published
- 2022
27. Evaluation of the Effects of Microgravity on Activated Primary Human Hepatic Stellate Cells
- Author
-
Koichi Fujisawa, Yuto Nishimura, Akino Sakuragi, Jolien Duponselle, Toshihiko Matsumoto, Naoki Yamamoto, Tomoaki Murata, Isao Sakaida, and Taro Takami
- Subjects
Weightlessness ,Organic Chemistry ,Biology and Life Sciences ,General Medicine ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,hepatic stellate cell ,microgravity ,transcriptome ,Hepatic Stellate Cells ,Medicine and Health Sciences ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Weightlessness Simulation ,Spectroscopy ,Cell Proliferation - Abstract
In recent years, research has been conducted to develop new medical treatments by simulating environments existing in space, such as zero-gravity. In this study, we evaluated the cell proliferation and gene expression of activated primary human hepatic stellate cells (HHSteCs) under simulated microgravity (SMG). Under SMG, cell proliferation was slower than in 1 G, and the evaluation of gene expression changes on day 1 of SMG by serial analysis of gene expression revealed the presence of Sirtuin, EIF2 signaling, hippo signaling, and epithelial adherence junction signaling. Moreover, reactive oxygen species were upregulated under SMG, and when N-acetyl-cystein was added, no difference in proliferation between SMG and 1 G was observed, suggesting that the oxidative stress generated by mitochondrial dysfunction caused a decrease in proliferation. Upstream regulators such as smad3, NFkB, and FN were activated, and cell-permeable inhibitors such as Ly294002 and U0126 were inhibited. Immunohistochemistry performed to evaluate cytoskeletal changes showed that more β-actin was localized in the cortical layer under SMG.
- Published
- 2022
- Full Text
- View/download PDF
28. Rectal Metastasis of Renal Cell Carcinoma
- Author
-
Sho Sasaki, Kazuo Mizumoto, Akira Sasaki, and Taro Takami
- Subjects
Rectal Neoplasms ,Internal Medicine ,Humans ,General Medicine ,Carcinoma, Renal Cell ,Nephrectomy ,Kidney Neoplasms - Published
- 2022
29. Seasonal variations in photoperiod affect hepatic metabolism of medaka (Oryzias latipes)
- Author
-
Taro Takami, Haruko Shintani, Naoki Yamamoto, Nanami Sasai, Koichi Fujisawa, Isao Sakaida, and Toshihiko Matsumoto
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Oryzias ,Photoperiod ,Citric Acid Cycle ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Metabolome ,Lipolysis ,Animals ,Metabolomics ,lcsh:QH301-705.5 ,Research Articles ,fatty liver ,medaka ,biology ,Chemistry ,Fatty liver ,Fatty Acids ,Lipid metabolism ,Metabolism ,biology.organism_classification ,medicine.disease ,Lipid Metabolism ,Citric acid cycle ,030104 developmental biology ,Endocrinology ,lcsh:Biology (General) ,Liver ,Seafood ,030220 oncology & carcinogenesis ,tricarboxylic acid cycle ,Seasons ,Steatosis ,Energy Metabolism ,Research Article - Abstract
Organisms living in temperate regions are sensitive to seasonal variations in the environment; they are known to accumulate energy as fat in their livers during the winter when days are shorter, temperatures are lower, and food is scarce. However, the effect of variations in photoperiod alone on hepatic lipid metabolism has not been well studied. Therefore, in this study, we analyzed lipid metabolism in the liver of medaka, Oryzias latipes, while varying the length of days at constant temperature. Larger amounts of fatty acids accumulated in the liver after 14 days under short‐day conditions than under long‐day conditions. Metabolome analysis showed no accumulation of long‐chain unsaturated fatty acids, but showed a significant accumulation of long‐chain saturated fatty acids. Short‐day conditions induced a reduction in the levels of succinate, fumarate, and malate in the tricarboxylic acid cycle, decreased expression of PPARα, and decreased accumulation of acylcarnitine, which suggested inhibition of lipolysis. In addition, transparent medaka fed on a high‐fat diet under short‐day conditions exhibited greater amounts of fat accumulation and developed fatty liver. The findings of our study will be useful for creating a medaka hepatic steatosis model for future studies of hepatic steatosis‐related diseases., In this study, we analyzed lipid metabolism in the liver of medaka, Oryzias latipes, while varying the length of days at constant temperature. Larger amounts of fatty acids accumulated in the liver after 14 days under short‐day conditions than under long‐day conditions. The findings of our study will be useful for creating a medaka hepatic steatosis model for future studies of hepatic steatosis‐related diseases.
- Published
- 2021
30. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer
- Author
-
Seiji Kaino, Hiroto Matsui, Shigeyuki Suenaga, Tomomi Hoshida, Ikuei Fujii, Yutaka Suehiro, Taro Takami, Shingo Higaki, Hiroaki Nagano, Yuko Fujimoto, Takahiro Yamasaki, Chieko Suzuki, Toshihiko Matsumoto, Isao Sakaida, and Takanori Tsuyama
- Subjects
Cancer Research ,Cord ,Pancreatic disease ,business.industry ,General Medicine ,medicine.disease ,Bisulfite ,Oncology ,Pancreatic cancer ,DNA methylation ,Cancer research ,medicine ,Biomarker (medicine) ,Digital polymerase chain reaction ,CA19-9 ,business - Abstract
Background: Although serum carbohydrate antigen 19-9 (CA19-9) is widely used as a useful biomarker of pancreatic cancer for monitoring the response to therapy, it is not recommended for screening of early pancreatic cancer because of its limited sensitivity for small tumors. Thus, it is critical to discover novel serum biomarkers to complement CA19-9 in order to improve sensitivity. Although methylated runt-related transcription factor 3 (RUNX3) is a biomarker of pancreatic cancer, its detection by conventional bisulfite-based methylation assays from a small serum sample amount is very difficult. Therefore, we developed a new methylation assay, the combined restriction digital PCR (CORD) assay, that enables counting of even one copy of a methylated gene in a small DNA sample amount without DNA bisulfite treatment. Objectives: We evaluated the sensitivity and specificity of serum DNA testing of methylated RUNX3 by the CORD assay in combination with and without CA19-9 for the detection of pancreatic cancer in 55 patients with pancreatic cancer, 12 patients with benign pancreatic disease, and 80 healthy individuals. Results: The CORD assay of methylated RUNX3 had a sensitivity of 50.9% (28/55) and specificity of 93.5% (86/92). Combination of the CORD assay of methylated RUNX3 and CA19-9 resulted in a sensitivity of 85.5% (47/55) and specificity of 93.5% (86/92) for all stages of pancreatic cancer and a sensitivity of 77.8% (7/9) for stage I pancreatic cancer. Conclusions: ombination of the CORD assay and CA19-9 may provide an alternative screening strategy for detecting early-stage pancreatic cancer.
- Published
- 2021
31. Mesenchymal Stem Cells Induce a Fibrolytic Phenotype By Regulating mmu-miR-6769b-5p Expression in Macrophages
- Author
-
Koichi Fujisawa, Isao Sakaida, Yutaka Suehiro, Naoki Yamamoto, Toshihiko Matsumoto, Taro Takami, Maiko Nishi, and Takahiro Yamasaki
- Subjects
Lipopolysaccharides ,Male ,0301 basic medicine ,medicine.medical_treatment ,Down-Regulation ,Economic shortage ,Liver transplantation ,Biology ,Extracellular Vesicles ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,medicine ,Animals ,Radical treatment ,Fibrin ,Macrophages ,ATF4 ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Cell Biology ,Hematology ,medicine.disease ,Decompensated cirrhosis ,Activating Transcription Factor 4 ,Phenotype ,Coculture Techniques ,Up-Regulation ,Mice, Inbred C57BL ,MicroRNAs ,030104 developmental biology ,Gene Expression Regulation ,Matrix Metalloproteinase 9 ,Cancer research ,Cytokines ,Inflammation Mediators ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
Liver transplantation is the only radical treatment for decompensated cirrhosis, but its use is limited owing to a shortage of donors; hence, there is an urgent need for new treatments. Previously, we developed a liver-regeneration therapy using autologous bone marrow-derived mesenchymal stem cells (BMSCs), which is under clinical investigation. Cell-cell interactions between BMSCs and macrophages (Mφs) participate in the improvement of liver function and alleviation of liver fibrosis, although the associated mechanisms have not been elucidated. Therefore, in this study, we investigated phenotypic changes in Mφs caused by interactions with BMSCs, as well as the underlying mechanisms. Co-culturing lipopolysaccharide (LPS)-stimulated murine bone marrow-derived Mφs (BMDMs) with BMSCs substantially upregulated matrix metalloproteinase 9 (
- Published
- 2020
32. MC180295 Inhibited Epstein-Barr Virus-Associated Gastric Carcinoma Cell Growth by Suppressing DNA Repair and the Cell Cycle
- Author
-
Tomohiro Fujii, Jun Nishikawa, Soichiro Fukuda, Naoto Kubota, Junzo Nojima, Koichi Fujisawa, Ryo Ogawa, Atsushi Goto, Koichi Hamabe, Shinichi Hashimoto, Aung Phyo Wai, Hisashi Iizasa, Hironori Yoshiyama, Kohei Sakai, Yutaka Suehiro, Takahiro Yamasaki, and Taro Takami
- Subjects
Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,DNA Repair ,Organic Chemistry ,Carcinoma ,Cell Cycle ,DNA Helicases ,General Medicine ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Stomach Neoplasms ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy - Abstract
DNA methylation of both viral and host DNA is one of the major mechanisms involved in the development of Epstein–Barr virus-associated gastric carcinoma (EBVaGC); thus, epigenetic treatment using demethylating agents would seem to be promising. We have verified the effect of MC180295, which was discovered by screening for demethylating agents. MC180295 inhibited cell growth of the EBVaGC cell lines YCCEL1 and SNU719 in a dose-dependent manner. In a cell cycle analysis, growth arrest and apoptosis were observed in both YCCEL1 and SNU719 cells treated with MC180295. MKN28 cells infected with EBV were sensitive to MC180295 and showed more significant inhibition of cell growth compared to controls without EBV infection. Serial analysis of gene expression analysis showed the expression of genes belonging to the role of BRCA1 in DNA damage response and cell cycle control chromosomal replication to be significantly reduced after MC180295 treatment. We confirmed with quantitative PCR that the expression levels of BRCA2, FANCM, RAD51, TOP2A, and CDC45 were significantly decreased by MC180295. LMP1 and BZLF1 are EBV genes with expression that is epigenetically regulated, and MC180295 could up-regulate their expression. In conclusion, MC180295 inhibited the growth of EBVaGC cells by suppressing DNA repair and the cell cycle.
- Published
- 2022
33. Adenylate Kinase Isozyme 3 Regulates Mitochondrial Energy Metabolism and Knockout Alters HeLa Cell Metabolism
- Author
-
Koichi Fujisawa, Maina Wakazaki, Aya Matsuzaki, Toshihiko Matsumoto, Naoki Yamamoto, Takafumi Noma, and Taro Takami
- Subjects
Organic Chemistry ,Adenylate Kinase ,adenylate kinase 3 ,nucleotide metabolism ,phosphoenolpyruvate ,GTP metabolism ,General Medicine ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Isoenzymes ,Phosphoenolpyruvate ,Adenosine Triphosphate ,Humans ,Physical and Theoretical Chemistry ,Energy Metabolism ,Molecular Biology ,Spectroscopy ,Phosphoenolpyruvate Carboxykinase (ATP) ,HeLa Cells - Abstract
The balance between oxidative phosphorylation and glycolysis is important for cancer cell growth and survival, and changes in energy metabolism are an emerging therapeutic target. Adenylate kinase (AK) regulates adenine nucleotide metabolism, maintaining intracellular nucleotide metabolic homeostasis. In this study, we focused on AK3, the isozyme localized in the mitochondrial matrix that reversibly mediates the following reaction: Mg2+ GTP + AMP ⇌ Mg2+ GDP + ADP. Additionally, we analyzed AK3-knockout (KO) HeLa cells, which showed reduced proliferation and were detected at an increased number in the G1 phase. A metabolomic analysis showed decreased ATP; increased glycolytic metabolites such as glucose 6 phosphate (G6P), fructose 6 phosphate (F6P), and phosphoenolpyruvate (PEP); and decreased levels of tricarboxylic acid (TCA) cycle metabolites in AK3KO cells. An intracellular ATP evaluation of AK3KO HeLa cells transfected with ATeam plasmid, an ATP sensor, showed decreased whole cell levels. Levels of mitochondrial DNA (mtDNA), a complementary response to mitochondrial failure, were increased in AK3KO HeLa cells. Oxidative stress levels increased with changes in gene expression, evidenced as an increase in related enzymes such as superoxide dismutase 2 (SOD2) and SOD3. Phosphoenolpyruvate carboxykinase 2 (PCK2) expression and PEP levels increased, whereas PCK2 inhibition affected AK3KO HeLa cells more than wild-type (WT) cells. Therefore, we concluded that increased PCK2 expression may be complementary to increased GDP, which was found to be deficient through AK3KO. This study demonstrated the importance of AK3 in mitochondrial matrix energy metabolism.
- Published
- 2022
- Full Text
- View/download PDF
34. Gastric Ischemia Diagnosed by Contrast-enhanced Computed Tomography
- Author
-
Kazuhiro Yamamoto, Jun Nishikawa, Koichi Hamabe, and Taro Takami
- Subjects
Ischemia ,Stomach Neoplasms ,Stomach ,Internal Medicine ,Contrast Media ,Humans ,General Medicine ,Tomography, X-Ray Computed ,Retrospective Studies - Published
- 2022
35. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
- Author
-
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, and Hitoshi Yoshiji
- Subjects
cirrhosis ,hepatic encephalopathy ,Japanese ,long-term ,rifaximin ,General Medicine - Abstract
Background: Rifaximin is commonly used for hepatic encephalopathy (HE). However, the effects of long-term treatment for Japanese people are limited. Therefore, this study aimed to investigate the effects and safety of long-term treatment with rifaximin on HE. Methods: A total of 215 patients with cirrhosis administered with rifaximin developed overt or covert HE, which was diagnosed by an attending physician for >12 months. Laboratory data were extracted at pretreatment and 3, 6, and 12 months after rifaximin administration. The long-term effect of rifaximin was evaluated, and the incidence of overt HE during 12 months and adverse events was extracted. Results: Ammonia levels were significantly improved after 3 months of rifaximin administration and were continued until 12 months. There were no serious adverse events after rifaximin administration. The number of overt HE incidents was 9, 14, and 27 patients within 3, 6, and 12 months, respectively. Liver enzymes, renal function, and electrolytes did not change after rifaximin administration. Prothrombin activity is a significant risk factor for the occurrence of overt HE. The serum albumin, prothrombin activity, and albumin–bilirubin (ALBI) scores were statistically improved after 3 and 6 months of rifaximin administration. Moreover, the same results were obtained in patients with Child–Pugh C. Conclusions: The long-term rifaximin treatment was effective and safe for patients with HE, including Child–Pugh C.
- Published
- 2022
- Full Text
- View/download PDF
36. Flower in the duodenum (with video)
- Author
-
Koichi Hamabe, Jun Nishikawa, Atsushi Goto, Ryo Ogawa, Shinichi Hashimoto, Yoshinobu Hoshii, Michihisa Iida, Hiroaki Nagano, and Taro Takami
- Subjects
Duodenum ,Gastroenterology ,Humans ,Radiology, Nuclear Medicine and imaging ,Flowers - Published
- 2022
37. Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM–CHK2 Pathway
- Author
-
Yusuke Niwa, Kenya Kamimura, Kohei Ogawa, Chiyumi Oda, Yuto Tanaka, Ryoko Horigome, Masato Ohtsuka, Hiromi Miura, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Shujiro Okuda, Masayoshi Ko, Takashi Owaki, Atsushi Kimura, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, and Shuji Terai
- Subjects
Ccndbp1 ,Atm ,Ezh2 ,Chk2 ,DNA damage ,hepatocellular carcinoma ,Medicine ,General Medicine - Abstract
Cyclin D1 binding protein 1 (CCNDBP1) is considered a tumor suppressor, and when expressed in tumor cells, CCNDBP1 can contribute to the viability of cancer cells by rescuing these cells from chemotherapy-induced DNA damage. Therefore, this study focused on investigating the function of CCNDBP1, which is directly related to the survival of cancer cells by escaping DNA damage and chemoresistance. Hepatocellular carcinoma (HCC) cells and tissues obtained from Ccndbp1 knockout mice were used for the in vitro and in vivo examination of the molecular mechanisms of CCNDBP1 associated with the recovery of cells from DNA damage. Subsequently, gene and protein expression changes associated with the upregulation, downregulation, and irradiation of CCNDBP1 were assessed. The overexpression of CCNDBP1 in HCC cells stimulated cell growth and showed resistance to X-ray-induced DNA damage. Gene expression analysis of CCNDBP1-overexpressed cells and Ccndbp1 knockout mice revealed that Ccndbp1 activated the Atm–Chk2 pathway through the inhibition of Ezh2 expression, accounting for resistance to DNA damage. Our study demonstrated that by inhibiting EZH2, CCNDBP1 contributed to the activation of the ATM–CHK2 pathway to alleviate DNA damage, leading to chemoresistance.
- Published
- 2022
- Full Text
- View/download PDF
38. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study
- Author
-
Takahiro Kodama, Tomomi Yamada, Norifumi Kawada, Ryosuke Tateishi, Masayuki Kurosaki, Nobuyuki Enomoto, Yasuhiro Asahina, Tatsuya Kanto, Goki Suda, Taro Yamashita, Tetsuo Takehara, Hitoshi Yoshiji, Daiki Miki, Yasuhiro Takikawa, Taro Takami, Yoshito Itoh, Kazuhiko Nakao, Shuji Terai, Tomohide Tatsumi, Ryotaro Sakamori, Akio Ido, Yoichi Hiasa, Hiroshi Yatsuhashi, Ryoko Yamada, Yasunari Nakamoto, Satoshi Mochida, Kentaro Matsuura, Naoya Kato, Yoshiyuki Ueno, Masahito Shimizu, Hayato Hikita, Norio Akuta, and Yuki Tahata
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Sustained Virologic Response ,Sofosbuvir ,Hepatitis C virus ,Phases of clinical research ,medicine.disease_cause ,Antiviral Agents ,Heterocyclic Compounds, 4 or More Rings ,Gastroenterology ,Drug Administration Schedule ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Japan ,Internal medicine ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Hepatitis C, Chronic ,Middle Aged ,Hepatology ,medicine.disease ,Discontinuation ,Drug Combinations ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Carbamates ,Liver function ,business ,Follow-Up Studies ,medicine.drug - Abstract
Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir (SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated cirrhosis are limited in Japan. A total of 190 patients with compensated (108) or decompensated (82) cirrhosis who initiated direct-acting antiviral (DAA) treatment between February 2019 and August 2019 were enrolled. Sustained virologic response (SVR) was defined as undetectable serum HCV-RNA at 12 weeks after the end of treatment (EOT). The SVR12 rates were 92.6% in patients with compensated cirrhosis and 90.2% in patients with decompensated cirrhosis (p = 0.564), and the treatment completion rates were 98.1% and 96.3%, respectively (p = 0.372). In patients with decompensated cirrhosis, 3 patients discontinued treatment and 2 patients died because of liver-related events. In patients with decompensated cirrhosis with SVR12, 50% of patients with Child–Pugh class B at baseline showed improvement to class A at SVR12, and 27% and 9% of patients with Child–Pugh class C at baseline showed improvement to class B and class A at SVR12, respectively. Patients who achieved SVR12 showed elevated serum albumin levels at the EOT, which were further elevated at SVR12, but no elevated serum albumin levels after the EOT were observed in patients with baseline serum albumin levels less than 2.8 g/dl. Real-world efficacy of SOF/VEL treatment for patients with decompensated cirrhosis was similar to Japanese phase 3 study, although treatment discontinuation and death related to liver disease occurred. In patients with poor hepatic reserve, whether it improves continuously after viral clearance requires further evaluation.
- Published
- 2020
39. Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model
- Author
-
Isao Sakaida, Ryo Sasaki, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Naoki Yamamoto, Taro Takami, and Koichi Fujisawa
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Cirrhosis ,macrophage polarization ,Clinical Biochemistry ,Serum albumin ,Medicine (miscellaneous) ,CCL4 ,Spleen ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,oxidative stress ,nonalcoholic steatohepatitis ,Sirius Red ,mesenchymal stem cell ,liver fibrosis ,030109 nutrition & dietetics ,Nutrition and Dietetics ,biology ,business.industry ,medicine.disease ,medicine.anatomical_structure ,Endocrinology ,chemistry ,Carbon tetrachloride ,biology.protein ,030211 gastroenterology & hepatology ,Original Article ,Bone marrow ,Steatohepatitis ,business - Abstract
The incidence of nonalcoholic steatohepatitis-related liver cirrhosis is increasing. We used a steatohepatitis murine model fed a choline-deficient, l-amino acid-defined (CDAA) diet with a single injection of carbon tetrachloride (CCl4) to evaluate the efficacy of trans-portal hepatic infusion of bone marrow-derived mesenchymal stem cells (BMSCs) for liver fibrosis, liver steatosis, and oxidative stress. Mice were fed a CDAA diet and injected with a single intraperitoneal dose of CCl4 (0.5 ml/kg) after 4 weeks of CDAA diet. After 12 weeks of CDAA diet, 1 × 106 luciferase-positive syngeneic BMSCs (Luc-BMSCs) were infused into the animal spleen. An in vivo imaging system was used to confirm Luc-BMSC accumulation in the liver via the portal vein, and at 4 weeks after infusion, we compared liver fibrosis, liver steatosis, and oxidative stress. After the BMSC-infusion, serum albumin and serum total bilirubin were significantly improved. Liver fibrosis assessed by Sirius red staining, α-smooth muscle actin protein, and collagen 1A1 mRNA expression was significantly suppressed. Furthermore, liver steatosis area was significantly lower, the 8-hydroxy-2'-deoxyguanosine-positive cells were significantly fewer, and superoxide dismutase 2 protein expression of the liver was significantly increased. In conclusion, our data confirmed the efficacy of trans-portal hepatic infusion of BMSCs in a steatohepatitis murine model.
- Published
- 2020
40. Evaluation of a symptom checklist for the early detection of symptoms in patients with chronic liver disease
- Author
-
Terumi Hamao, Takuya Iwamoto, Sumire Harano, Takashi Oono, Issei Saeki, Tsuyoshi Ishikawa, Isao Hidaka, Isao Sakaida, and Taro Takami
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Internal medicine ,Medicine ,Early detection ,In patient ,business ,Chronic liver disease ,medicine.disease ,Checklist - Published
- 2020
41. Significant improvement in portal‐systemic liver failure symptoms and successful management of portal‐splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy
- Author
-
Takuya Iwamoto, Kaori Hamamoto, Tatsuro Nishimura, Takashi Matsuda, Isao Sakaida, Ryo Sasaki, Taro Takami, and Tsuyoshi Ishikawa
- Subjects
medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,Portal venous pressure ,Hemodynamics ,Hyperammonemia ,Portal hypertensive gastropathy ,Interventional radiology ,Hepatitis C ,Splenic artery ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,030220 oncology & carcinogenesis ,medicine.artery ,Internal medicine ,Ascites ,medicine ,Cardiology ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Aim To describe a case of hepatitis C virus-related decompensated cirrhosis with portal-systemic liver failure and refractory encephalopathy that was successfully managed with a combination of interventional radiology and pharmacotherapy to improve hepatic function including hyperammonemia and to control portal-splenic venous hemodynamics with hepatic venous pressure gradient (HVPG) monitoring. Case presentation A man in his late 50s presented with a Child-Pugh score of 13, Model for End-Stage Liver Disease-sodium (MELD-Na) score of 19, and blood ammonia level of 185 μg/dL. He underwent balloon-occluded retrograde transvenous obliteration (BRTO) followed by partial splenic embolization (PSE) and non-selective beta-blocker (NSBB) administration. BRTO induced drastic changes in the portal-splenic venous hemodynamics, resulting in dramatically improved hepatic function and reduced hyperammonemia. However, the procedure resulted in increased HVPG from 13.6 mmHg at baseline to 23.5 mmHg at 1-month post-BRTO, accompanied by ascites retention and portal hypertensive gastropathy (PHG) development. Thereafter, PSE was performed, followed by NSBB administration, to control the elevated portal venous pressure following BRTO. Postoperatively, the patient's ascites and PHG improved after splenic artery embolization, which eventually disappeared after the additional administration of NSBBs at 1 month later. The HVPG finally decreased to 16.9 mmHg, and Child-Pugh score, MELD-Na score, and blood ammonia level improved to 7, 11, and 22 μg/dL, respectively, after all therapies. Conclusion BRTO significantly improved the symptoms of portal-systemic liver failure with refractory encephalopathy. PSE and NSBB administration could contribute to additional amelioration of hepatic function and successful management of complications induced by portal hemodynamic changes following BRTO.
- Published
- 2020
42. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
- Author
-
Koichi Fujisawa, Hirofumi Harima, Toshihiko Matsumoto, Taro Takami, Shuhei Shinoda, Isao Sakaida, Takahiro Yamasaki, Naoki Yamamoto, Shogo Amano, and Seiji Kaino
- Subjects
rac1 GTP-Binding Protein ,Cancer Research ,Cancer therapy ,Cell Survival ,Motility ,RAC1 ,CDC42 ,In Vitro Techniques ,Iron Chelating Agents ,lcsh:RC254-282 ,Rho family protein ,Invasion ,Cell Movement ,In vivo ,Cell Line, Tumor ,Pancreatic cancer ,Genetics ,medicine ,Humans ,Neoplasm Invasiveness ,cdc42 GTP-Binding Protein ,business.industry ,Deferasirox ,Microarray Analysis ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,In vitro ,Pancreatic Neoplasms ,Oncology ,Cancer cell ,Cancer research ,Iron chelation ,business ,Research Article ,medicine.drug - Abstract
Background Iron is required for cellular metabolism, and rapidly proliferating cancer cells require more of this essential nutrient. Therefore, iron regulation may well represent a new avenue for cancer therapy. We have reported, through in vitro and in vivo research involving pancreatic cancer cell lines, that the internal-use, next-generation iron chelator deferasirox (DFX) exhibits concentration-dependent tumour-suppressive effects, among other effects. After performing a microarray analysis on the tumour grafts used in that research, we found that DFX may be able to suppress the cellular movement pathways of pancreatic cancer cells. In this study, we conducted in vitro analyses to evaluate the effects of DFX on the invasive and migratory abilities of pancreatic cancer cells. Methods We used pancreatic cancer cell lines (BxPC-3, Panc-1, and HPAF II) to examine the efficacy of DFX in preventing invasion in vitro, evaluated using scratch assays and Boyden chamber assays. In an effort to understand the mechanism of action whereby DFX suppresses tumour invasion and migration, we performed G-LISA to examine the activation of Cdc42 and Rac1 which are known for their involvement in cellular movement pathways. Results In our scratch assays, we observed that DFX-treated cells had significantly reduced invasive ability compared with that of control cells. Similarly, in our Boyden chamber assays, we observed that DFX-treated cells had significantly reduced migratory ability. After analysis of the Rho family of proteins, we observed a significant reduction in the activation of Cdc42 and Rac1 in DFX-treated cells. Conclusions: DFX can suppress the motility of cancer cells by reducing Cdc42 and Rac1 activation. Pancreatic cancers often have metastatic lesions, which means that use of DFX will suppress not only tumour proliferation but also tumour invasion, and we expect that this will lead to improved prognoses.
- Published
- 2020
43. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma
- Author
-
Yutaka Suehiro, Takuya Iwamoto, Masaki Maeda, Yurika Kotoh, Isao Hidaka, Shingo Higaki, Takahiro Yamasaki, Chieko Suzuki, Tsuyoshi Ishikawa, Hiroaki Nagano, Issei Saeki, Taro Takami, Toshihiko Matsumoto, Isao Sakaida, Tomomi Hoshida, Yukio Tokumitsu, Yoshitaro Shindo, and Ikuei Fujii
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Assay sensitivity ,medicine.disease ,Chronic liver disease ,Gastroenterology ,Hepatocellular carcinoma ,Internal medicine ,medicine ,lcsh:Diseases of the digestive system. Gastroenterology ,Digital polymerase chain reaction ,Multiplex ,lcsh:RC799-869 ,Stage (cooking) ,Liquid biopsy ,Liver cancer ,business - Abstract
Liquid biopsies are not used in practice for hepatocellular carcinoma (HCC). Epi proColon is the first commercial blood‐based test for colorectal cancer screening based on methylated DNA testing of the septin 9 gene (SEPT9). However, Epi proColon has some disadvantages, including the requirement of a large amount of blood and lack of quantitative performance. Therefore, we previously developed a novel liquid biopsy test that can quantitatively detect even a single copy of methylated SEPT9 in a small amount of DNA. In the current study, we evaluated the application potential of this assay for diagnosing HCC. Study subjects included 80 healthy volunteers, 45 patients with chronic liver disease (CLD) without HCC, and 136 patients with HCC (stage 0, 12; stage A, 50; stage B, 31; stage C, 41; and stage D, 2), according to the Barcelona Clinic Liver Cancer staging system. For the assay, DNA was treated with methylation‐sensitive restriction enzymes in two steps, followed by multiplex droplet digital polymerase chain reaction. The median copy number of methylated SEPT9 was 0.0, 2.0, and 6.4 in the healthy control, CLD, and HCC groups, respectively, with significant differences among the groups (HCC vs. healthy control, P
- Published
- 2020
44. Bone marrow-derived humoral factors suppress oxidative phosphorylation, upregulate TSG-6, and improve therapeutic effects on liver injury of mesenchymal stem cells
- Author
-
Takashi Miyaji, Isao Sakaida, Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, and Naoki Yamamoto
- Subjects
0301 basic medicine ,Liver injury ,030109 nutrition & dietetics ,Nutrition and Dietetics ,biology ,business.industry ,Clinical Biochemistry ,Mesenchymal stem cell ,Medicine (miscellaneous) ,medicine.disease ,Regenerative medicine ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Downregulation and upregulation ,microRNA ,Sirtuin ,Cancer research ,medicine ,biology.protein ,Original Article ,030211 gastroenterology & hepatology ,Bone marrow ,business ,Whole Bone Marrow - Abstract
Mesenchymal stem cells, which have the potential to be used in regenerative medicine, require improvements in quality for patient use. To maintain stemness of cultured bone marrow-derived mesenchymal stem cells, we focused on the bone marrow microenvironment, generated a conditioned medium of whole bone marrow cells (BMC-CM), and assessed its effects on bone marrow-derived mesenchymal stem cells. BMC-CM suppressed morphological deterioration and proliferative decline in cultured bone marrow-derived mesenchymal stem cells, suppressed mitochondrial oxidative phosphorylation activity, a stemness indicator, and upregulated suppressors of oxidative phosphorylation such as hypoxia-inducible factor-1 alpha, Sirtuin 3, 4, and 5. Furthermore, BMC-CM upregulated TNF-stimulated gene 6 and ameliorated the therapeutic effects of cells on liver injury in carbon tetrachloride-administered rats. Since the elimination of 20-220-nm particles attenuated the effects of BMC-CM, we further analyzed exosomal microRNAs produced by whole bone marrow cells. Among the 49 microRNAs observed to be upregulated during the preparation of BMC-CM, several were identified that were associated with suppression of oxidative phosphorylation, upregulation of TNF-stimulated gene 6, and the pathogenesis of liver diseases. Thus, bone marrow-derived humoral factors including exosomal microRNAs may help to improve the therapeutic quality of bone marrow-derived mesenchymal stem cells for liver regenerative therapy.
- Published
- 2020
45. The bactericidal effect of far-UVC on ESBL-producing Escherichia coli
- Author
-
Soichiro Fukuda, Jun Nishikawa, Yuki Kobayashi, Yumi Okabe, Tomohiro Fujii, Naoto Kubota, Ken-Ichiro Otsuyama, Hidehiro Tsuneoka, Shinichi Hashimoto, Yutaka Suehiro, Takahiro Yamasaki, and Taro Takami
- Subjects
Infectious Diseases ,Epidemiology ,Health Policy ,Public Health, Environmental and Occupational Health - Abstract
Because extended-spectrum beta-lactamase (ESBL) infections can cause life-threatening disease and effective treatments need to be developed, we examined the bactericidal effect of far-ultraviolet C (far-UVC) light therapy on ESBL-producing Escherichia coli (E. coli). The bactericidal effect on 2 types of ESBL-producing E. coli was the same as that on the wild strain although the results of drug resistance tests varied among these strains. We believe that irradiation with far-UVC is effective in preventing infection by ESBL-producing E. coli in health care settings.
- Published
- 2022
46. Optimizing the Seeding Density of Human Mononuclear Cells to Improve the Purity of Highly Proliferative Mesenchymal Stem Cells
- Author
-
Hiroyuki Nagai, Akihiro Miwa, Kenji Yoneda, Koichi Fujisawa, and Taro Takami
- Subjects
MSC ,cell isolation ,mononuclear cell ,colony ,Bioengineering - Abstract
Mesenchymal stem cells (MSCs) hold considerable promise for regenerative medicine. Optimization of the seeding density of mononuclear cells (MNCs) improves the proliferative and differentiation potential of isolated MSCs. However, the underlying mechanism is unclear. We cultured human bone marrow MNCs at various seeding densities (4.0 × 104, 1.25 × 105, 2.5 × 105, 6.0 × 105, 1.25 × 106 cells/cm2) and examined MSC colony formation. At lower seeding densities (4.0 × 104, 1.25 × 105 cells/cm2), colonies varied in diameter and density, from dense to sparse. In these colonies, the proportion of highly proliferative MSCs increased over time. In contrast, lower proliferative MSCs enlarged more rapidly. Senescent cells were removed using a short detachment treatment. We found that these mechanisms increase the purity of highly proliferative MSCs. Thereafter, we compared MSCs isolated under optimized conditions with a higher density (1.25 × 106 cells/cm2). MSCs under optimized conditions exhibited significantly higher proliferative and differentiation potential into adipocytes and chondrocytes, except for osteocytes. We propose the following conditions to improve MSC quality: (1) optimizing MNC seeding density to form single-cell colonies; (2) adjusting incubation times to increase highly proliferative MSCs; and (3) establishing a detachment processing time that excludes senescent cells.
- Published
- 2023
47. Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report
- Author
-
Taro Takami, Takuya Iwamoto, Issei Saeki, Tsuyoshi Ishikawa, Isao Sakaida, and Isao Hidaka
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Hepatitis C virus ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Radiography, Interventional ,medicine.disease_cause ,Gastroenterology ,Hypersplenism ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Embolization ,Hepatic encephalopathy ,Aged ,Cytopenia ,medicine.diagnostic_test ,business.industry ,Hyperammonemia ,Interventional radiology ,Articles ,General Medicine ,Hepatitis C Antibodies ,medicine.disease ,Hepatitis C ,Hepatic Encephalopathy ,030220 oncology & carcinogenesis ,Splenomegaly ,business - Abstract
Patient: Male, 72 Final Diagnosis: Decompensated liver cirrhosis Symptoms: Disturbance of consciousness Medication: — Clinical Procedure: PSE • BRTO • HCV treatment Specialty: Radiology Objective: Unusual clinical course Background: The appearance of direct acting antivirals (DAAs) has produced a major paradigm shift in hepatitis C virus (HCV) infection treatment, and virus elimination has become possible in most patients. Improvement of the model for end-stage liver disease (MELD) score by elimination of HCV has been reported, but for decompensated liver cirrhosis, it is also important to overcome various complications before antiviral treatment. Case Report: A 72-year-old male, who had been treated for HCV-related liver cirrhosis was referred to our hospital for treatment of refractory hepatic encephalopathy. At that time, his Child-Pugh score was 10 and class was C. On contrast-enhanced computed tomography (CT), a splenorenal shunt, splenomegaly, and splenic artery aneurysm were noted. The disease was also complicated by cytopenia associated with hypersplenism, and embolization of the splenic artery aneurysm and partial splenic embolization (PSE) were concomitantly performed. One month after the PSE, balloon occluded retrograde transvenous obliteration (BRTO) for refractory hepatic encephalopathy was performed. Hepatic functional reserve improved compared with that at the first examination, and SOF/LDV therapy was initiated. Fortunately, no adverse effect occurred during treatment, and sustained virologic response (SVR) was achieved. Hepatic functional reserve further improved thereafter. At the time of this report, a Child-Pugh A status was being maintained without administration of a branched chain amino acid preparation, drugs for hyperammonemia, or diuretics. Conclusions: We encountered a patient with decompensated liver cirrhosis accompanied by complications of hypersplenism, hepatic encephalopathy, and splenic artery aneurysm. These complications were overcome by treatment with PSE and BRTO, which led to DAAs treatment and a marked improvement of hepatic function.
- Published
- 2019
48. Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs
- Author
-
Ko NAKASUMI, Naoki YAMAMOTO, Taro TAKAMI, Harumichi ITOH, Kazuhito ITAMOTO, Hiro HORIKIRIZONO, Toshie ISERI, Munekazu NAKAICHI, Yuki NEMOTO, Hiroshi SUNAHARA, and Kenji TANI
- Subjects
Carcinoma, Hepatocellular ,Dogs ,Hepatic Artery ,Treatment Outcome ,General Veterinary ,Pharmaceutical Preparations ,Doxorubicin ,Liver Neoplasms ,Animals ,Dog Diseases ,Chemoembolization, Therapeutic ,Cisplatin - Abstract
Transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) are standard treatments for advanced hepatocellular carcinoma (HCC) and particularly for unresectable tumors or liver metastases in humans. However, reports on TACE used in veterinary medicine are few. This study aimed to evaluate the feasibility and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE). We performed DEB-TACE in four clinically normal dogs and pharmacokinetically compared the results against hepatic arterial infusion (HAI) of cisplatin in two dogs. Drug-eluting beads (DEB) loaded with cisplatin were injected through a microcatheter for selective embolization of the left hepatic artery. After embolization, computed tomography (CT) images and histological examination findings were obtained during a 4-week observation period. Serum platinum concentrations were measured to evaluate cisplatin after each procedure. Biochemical analysis was performed during a 12-week observation period. Embolization was successful in all dogs, and there were no clinically apparent abnormalities. Embolization was confirmed up to 4 weeks after DEB-TACE in two of the four dogs and up to 1 week in the other two dogs using postoperative CT images. Cisplatin was not detected in peripheral veins in all dogs after DEB-TACE, but it was detected in trace amounts after HAI. DEB-TACE using cisplatin was safe and well tolerated by normal dogs. DEB-TACE may be useful in terms of determining systemic toxicity and drug concentration within tumors.
- Published
- 2021
49. Safety and efficacy of capsule endoscopy for patients with newly diagnosed Crohn's disease: A multicenter retrospective study
- Author
-
Seiji Kawano, Shiro Oka, Akiko Shiotani, Shinichi Hashimoto, Sakuma Takahashi, Osamu Handa, Taro Takami, Tomoki Inaba, Hiroyuki Okada, and Shinji Tanaka
- Subjects
young patients ,Crohn's disease ,upper small intestine ,capsule endoscopy ,General Medicine - Abstract
Crohn's disease (CD) is a chronic inflammatory disease that develops at a young age and frequently leads to intestinal resection. Capsule endoscopy (CE) can directly and non-invasively inspect the entire small bowel mucosa. We suspected that CE could be a good diagnostic tool for detecting CD in young patients. The aim of this study was to investigate the safety and efficacy of CE in patients with newly diagnosed CD and to evaluate the CE findings, especially in the upper small bowel of young patients. We retrospectively investigated 32 patients with newly diagnosed CD from 5 institutions. Patient characteristics, clinical course, and characteristics of CE findings were analyzed. The total small intestine observation rate was 93%, and the retention rate was 3% (1/32). No abnormality was identified by ileocolonoscopy in 46% (15/32), and transition of small bowel lesions (TSL) was found in 35% (12/34) of the patients. The frequency of longitudinal ulcers and cobblestones in the upper small intestine was significantly higher in younger patients (
- Published
- 2022
50. The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis
- Author
-
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Norifumi Kawada, Masayuki Kurosaki, Akio Ido, Hitoshi Yoshiji, Daiki Miki, Yasuhiro Takikawa, Ryotaro Sakamori, Yoichi Hiasa, Hiroshi Yatsuhashi, Kazuhiko Nakao, Naoya Kato, Yoshiyuki Ueno, Yoshito Itoh, Ryosuke Tateishi, Goki Suda, Taro Takami, Kentaro Matsuura, Taro Yamashita, Norio Akuta, Tatsuya Kanto, Yasunari Nakamoto, Yasuhiro Asahina, Shuji Terai, Masahito Shimizu, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, and Tetsuo Takehara
- Subjects
Hepatology - Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.